brinzolamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
396 138890-62-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • AL-4862
  • brinzolamide
  • azopt
an antiglaucoma agent
  • Molecular weight: 383.50
  • Formula: C12H21N3O5S3
  • CLOGP: 0.33
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 118.80
  • ALOGS: -2.73
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 ml None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 1, 1998 FDA ALCON PHARMS LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 400.75 19.27 217 6603 92870 46586372
Intraocular pressure increased 366.52 19.27 98 6722 5859 46673383
Eye irritation 351.55 19.27 120 6700 16494 46662748
Ocular hyperaemia 240.66 19.27 95 6725 19615 46659627
Glaucoma 188.22 19.27 75 6745 15846 46663396
Eye pain 171.57 19.27 83 6737 27857 46651385
Vision blurred 129.43 19.27 101 6719 79607 46599635
Foreign body sensation in eyes 83.66 19.27 24 6796 1852 46677390
Product delivery mechanism issue 83.63 19.27 17 6803 297 46678945
Eye allergy 80.15 19.27 18 6802 513 46678729
Eye pruritus 77.98 19.27 37 6783 11861 46667381
Visual impairment 74.12 19.27 68 6752 66621 46612621
Punctate keratitis 72.57 19.27 17 6803 586 46678656
Cataract 68.14 19.27 55 6765 45360 46633882
Visual acuity reduced 66.52 19.27 41 6779 22072 46657170
Blindness 64.98 19.27 37 6783 17232 46662010
Eye discharge 57.43 19.27 23 6797 4905 46674337
Product physical consistency issue 50.02 19.27 12 6808 459 46678783
Corneal oedema 47.26 19.27 15 6805 1631 46677611
Floppy iris syndrome 46.47 19.27 9 6811 121 46679121
Eyelid margin crusting 45.59 19.27 12 6808 671 46678571
Conjunctival hyperaemia 44.47 19.27 15 6805 1974 46677268
Product container issue 41.93 19.27 14 6806 1785 46677457
Product quality issue 40.83 19.27 37 6783 35611 46643631
Ocular discomfort 38.28 19.27 15 6805 3020 46676222
Erythema of eyelid 37.56 19.27 13 6807 1848 46677394
Iridocyclitis 36.64 19.27 13 6807 1987 46677255
Corneal opacity 35.77 19.27 10 6810 702 46678540
Dry eye 35.76 19.27 32 6788 30290 46648952
Product packaging quantity issue 35.23 19.27 11 6809 1133 46678109
Corneal disorder 34.77 19.27 12 6808 1691 46677551
Intraocular pressure decreased 34.50 19.27 7 6813 121 46679121
Visual field defect 34.08 19.27 17 6803 6066 46673176
Uveitis 33.80 19.27 19 6801 8622 46670620
Endophthalmitis 33.75 19.27 14 6806 3264 46675978
Liquid product physical issue 32.78 19.27 9 6811 591 46678651
Hypotonia 31.94 19.27 18 6802 8211 46671031
Eyelid irritation 31.87 19.27 8 6812 370 46678872
Eyelash thickening 31.75 19.27 5 6815 17 46679225
Toxic epidermal necrolysis 31.32 19.27 26 6794 22252 46656990
Hypersensitivity 30.98 19.27 68 6752 150253 46528989
Eye swelling 29.39 19.27 24 6796 20079 46659163
Eye disorder 29.38 19.27 23 6797 18118 46661124
Product residue present 28.30 19.27 13 6807 3869 46675373
Product administration error 27.73 19.27 23 6797 19658 46659584
Intraocular pressure test abnormal 27.13 19.27 6 6814 159 46679083
Bradycardia 26.49 19.27 40 6780 66258 46612984
Chondropathy 25.78 19.27 10 6810 1960 46677282
Hyperaesthesia 24.72 19.27 15 6805 7841 46671401
Keratitis 23.54 19.27 10 6810 2473 46676769
Somnolence 22.83 19.27 62 6758 156459 46522783
Laryngeal stenosis 22.79 19.27 7 6813 683 46678559
Conjunctivitis 21.68 19.27 18 6802 15406 46663836
Visual acuity reduced transiently 21.61 19.27 5 6815 163 46679079
Deep anterior chamber of the eye 21.42 19.27 3 6817 3 46679239
Lacrimation increased 21.24 19.27 18 6802 15843 46663399
Eyelid oedema 20.94 19.27 15 6805 10342 46668900
Duodenal ulcer haemorrhage 20.54 19.27 9 6811 2399 46676843
Accidental exposure to product 20.52 19.27 20 6800 21061 46658181
Eye inflammation 19.45 19.27 10 6810 3799 46675443

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 363.46 19.20 151 4395 34528 29913404
Intraocular pressure increased 358.52 19.20 94 4452 5026 29942906
Eye irritation 174.60 19.20 55 4491 5641 29942291
Ocular hyperaemia 172.21 19.20 61 4485 8982 29938950
Eye pain 121.91 19.20 51 4495 11738 29936194
Vision blurred 100.04 19.20 68 4478 41748 29906184
Glaucoma 94.28 19.20 35 4511 5873 29942059
Visual acuity reduced 83.58 19.20 43 4503 15803 29932129
Corneal oedema 81.76 19.20 22 4524 1290 29946642
Uveitis 74.93 19.20 29 4517 5448 29942484
Visual impairment 73.93 19.20 50 4496 30388 29917544
Punctate keratitis 70.79 19.20 15 4531 311 29947621
Foreign body sensation in eyes 68.23 19.20 16 4530 533 29947399
Eye pruritus 58.03 19.20 22 4524 3905 29944027
Intraocular pressure decreased 53.28 19.20 10 4536 108 29947824
Corneal disorder 52.37 19.20 14 4532 800 29947132
Product delivery mechanism issue 52.09 19.20 10 4536 123 29947809
Product quality issue 48.34 19.20 32 4514 18742 29929190
Liquid product physical issue 44.49 19.20 10 4536 275 29947657
Erythema of eyelid 41.31 19.20 11 4535 619 29947313
Eyelid margin crusting 39.03 19.20 8 4538 140 29947792
Conjunctival hyperaemia 38.25 19.20 14 4532 2253 29945679
Hypersensitivity 33.31 19.20 41 4505 53987 29893945
Choroidal detachment 31.78 19.20 8 4538 360 29947572
Pyelitis 30.94 19.20 6 4540 78 29947854
Eye discharge 30.47 19.20 11 4535 1702 29946230
Eye allergy 29.39 19.20 5 4541 29 29947903
Ocular discomfort 29.20 19.20 10 4536 1325 29946607
Conjunctivitis 29.11 19.20 17 4529 7983 29939949
Blindness unilateral 27.54 19.20 13 4533 3959 29943973
Abnormal sensation in eye 27.21 19.20 8 4538 647 29947285
Cystoid macular oedema 26.86 19.20 8 4538 677 29947255
Keratitis 26.59 19.20 9 4537 1151 29946781
Ocular hypertension 25.95 19.20 8 4538 760 29947172
Conjunctivitis allergic 24.30 19.20 7 4539 527 29947405
Corneal erosion 23.91 19.20 5 4541 97 29947835
Cataract 23.00 19.20 22 4524 21813 29926119
Blindness 22.43 19.20 17 4529 12292 29935640
Eye infection 21.88 19.20 10 4536 2832 29945100
Flat anterior chamber of eye 19.79 19.20 4 4542 65 29947867
Eyelid irritation 19.68 19.20 4 4542 67 29947865
Product residue present 19.29 19.20 9 4537 2669 29945263

Pharmacologic Action:

SourceCodeDescription
ATC S01EC04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Carbonic anhydrase inhibitors
ATC S01EC54 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Carbonic anhydrase inhibitors
FDA MoA N0000000235 Carbonic Anhydrase Inhibitors
FDA EPC N0000175517 Carbonic Anhydrase Inhibitor
CHEBI has role CHEBI:23018 carbonate dehydratase inhibitor
CHEBI has role CHEBI:39456 antiglaucoma agent
MeSH PA D002257 Carbonic Anhydrase Inhibitors
MeSH PA D004791 Enzyme Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Acute nephropathy contraindication 58574008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.31 acidic
pKa2 7.75 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme INHIBITOR Ki 9.90 CHEMBL CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.52 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.40 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.96 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 7.30 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 7.62 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.55 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.44 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 8.52 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.52 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 9.05 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 8 CHEMBL
Alpha carbonic anhydrase Unclassified Ki 7.32 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 6.70 CHEMBL
Astrosclerin-3 Unclassified Ki 6.56 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 6.08 CHEMBL
Carbonic anhydrase Unclassified Ki 6.77 CHEMBL
Delta carbonic anhydrase Unclassified Ki 6.93 CHEMBL
Carbonic anhydrase Enzyme Ki 6.94 CHEMBL
Carbonic anhydrase Enzyme Ki 6.68 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.21 CHEMBL
Carbonic anhydrase Enzyme Ki 8.52 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.90 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.35 CHEMBL
Carbonic anhydrase Unclassified Ki 7.50 CHEMBL
Carbonic anhydrase Enzyme Ki 5.36 CHEMBL

External reference:

IDSource
9451Z89515 UNII
4021097 VUID
N0000148553 NUI
D00652 KEGG_DRUG
4021097 VANDF
C0673967 UMLSCUI
CHEBI:3176 CHEBI
BZ1 PDB_CHEM_ID
CHEMBL220491 ChEMBL_ID
DB01194 DRUGBANK_ID
68844 PUBCHEM_CID
7532 INN_ID
C111827 MESH_SUPPLEMENTAL_RECORD_UI
6797 IUPHAR_LIGAND_ID
194881 RXNORM
11638 MMSL
234032 MMSL
4298 MMSL
007497 NDDF
108836002 SNOMEDCT_US
386925003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Azopt HUMAN PRESCRIPTION DRUG LABEL 1 0065-0275 SUSPENSION/ DROPS 10 mg OPHTHALMIC NDA 24 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0065-4147 SUSPENSION/ DROPS 10 mg OPHTHALMIC NDA 24 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0078-0904 SUSPENSION/ DROPS 10 mg OPHTHALMIC NDA 26 sections
Brinzolamide HUMAN PRESCRIPTION DRUG LABEL 1 0591-2127 SUSPENSION/ DROPS 10 mg OPHTHALMIC ANDA 24 sections
Brinzolamide HUMAN PRESCRIPTION DRUG LABEL 1 0781-6014 SUSPENSION/ DROPS 10 mg OPHTHALMIC NDA authorized generic 23 sections